Dompé Farmaceutici

Dompé Farmaceutici is an Italian biopharmaceutical company whose history, according to its official account, dates back more than 130 years to a pharmacy and pharmaceutical production laboratory in Milan. The company says it has grown from Milan’s first compounding pharmacy into an international business spanning primary care and biopharma. Its corporate identity combines a long pharmaceutical heritage with an emphasis on scientific research and innovation. The company describes its research and development work as addressing high-need therapeutic areas. Its stated disease focus includes ophthalmic, neurological and pain-related indications, and it highlights nerve growth factor (NGF) as an important element of its research. Dompé says it engineered and manufactured the first recombinant human nerve growth factor (rhNGF) after seven years of research. It also developed Exscalate, a virtual screening platform intended to accelerate drug screening and discovery. Dompé reports operating in 40 countries and having about 1,100 employees globally. Its official homepage lists 11 active clinical studies and states that it plans €1 billion of R&D investment for 2025–2028; it also gives 2025 sales of €1.704 billion. These figures are company-reported website statements. The company’s official site identifies the Italian legal entity as Dompé farmaceutici S.p.A., a single-shareholder company registered in Milan. It names Sergio Dompé as Executive President and Nathalie Dompé as Chief Executive Officer.

Dompé’s official history traces the company’s roots to the late nineteenth century and to the Dompé family’s pharmaceutical work. It describes Gian Antonio Dompé as a pharmaceutical chemistry expert and his son, Onorato Dompé, as following in his footsteps through studies in chemistry, pharmaceutical chemistry and pharmacy at the Royal University in Turin. After graduating, Onorato established the Dompé-Adami pharmaceutical production laboratory in Milan. The official timeline marks 1890 as a period of pioneering pharmacy and industrial roots. In 1895, following the success of the laboratory, Onorato acquired the Farmacia Centrale in Milan’s Piazza della Scala. The business subsequently expanded its pharmacies to Palermo, Milan and Ponte Chiasso in Switzerland. In 1902, Onorato founded the Farmacie Inglesi Dompé chain, produced medicines according to the British school, and moved the growing production laboratory to another part of Milan near the city’s main hospital. The company’s history also credits Dompé with introducing new methods and products, including Ferro Indoloro. Dompé’s official history identifies Guaiacalcium, a cough medication launched in 1940, as its flagship product and the starting point for a portfolio of brands that grew over time. In the company’s present-day description, the business has developed from a Milan pharmacy into an international company spanning primary care and biopharma. It says its work now includes research and development in ophthalmic, neurological and pain-related areas, with NGF among its research interests. The company also describes its development of recombinant human nerve growth factor after seven years of research and the creation of Exscalate, a virtual screening platform for accelerating drug screening. The current official website describes Dompé as operating in 40 countries, with around 1,100 employees and 11 active clinical studies. It lists a planned €1 billion in R&D investment for 2025–2028 and reports 2025 sales of €1.704 billion. The site identifies Dompé farmaceutici S.p.A. as a single-shareholder company registered in Milan, Italy. Its management listing names Sergio Dompé as Executive President and Nathalie Dompé as Chief Executive Officer.

• 2025

  Company-reported scale and investment plans

• 1940

  Guaiacalcium launched

• 1902

  Farmacie Inglesi Dompé founded

• 1895

  Acquisition of Farmacia Centrale

• 1890

  Dompé family pharmaceutical roots

An international biopharmaceutical company combining a long pharmaceutical heritage with research-led work in ophthalmic, neurological and pain-related conditions.

• Guaiacalcium

  A cough medication launched in 1940, described by the company as its flagship product.

• Exscalate

  A virtual screening platform developed by Dompé to accelerate drug screening.

• Recombinant human nerve growth factor (rhNGF)

  Dompé says it engineered and manufactured the first rhNGF after seven years of research.

1. 1Biotech pharmaceutical company | Dompé Globaldompe.com
2. 2History: 130 years of pharmaceutical innovation | Dompé Globaldompe.com
3. 3Global Biopharmaceutical Company | Dompé Globaldompe.com
4. 4Our management team | Dompé Globaldompe.com